PDGFRB and non-small cell lung carcinoma: Of the effective anticancer drugs, dasatinib is an oral, small-molecule, Src family kinase (SFK) inhibitor that suppresses NSCLC progression via BRAF, PDGFR, ABL1, and DDR2 [33–38].